Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Acta Pharmacol Sin ; 44(4): 897-912, 2023 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-36280689

RESUMEN

Anti-vascular endothelial growth factor (VEGF) drugs have revolutionized the treatment of neovascular eye diseases, but responses are incomplete in some patients. Recent evidence shows that integrins are involved in the pathogenesis of neovascular age-related macular degeneration and diabetic retinopathy. JP1, derived from an optimized seven-amino-acid fragment of JWA protein, is a polypeptide specifically targeting integrin αVß3. In this study we evaluated the efficacy of JP1 on laser-induced choroidal neovascularization (CNV) and retinal vascular leakage. CNV mice received a single intravitreal (IVT) injection of JP1 (10, 20, 40 µg) or ranibizumab (RBZ, 10 µg). We showed that JP1 injection dose-dependently inhibited laser-induced CNV; the effect of RBZ was comparable to that of 20 µg JP1; a combined IVT injection of JP1 (20 µg) and RBZ (5 µg) exerted a synergistic effect on CNV. In the 3rd month after streptozotocin injection, diabetic mice receiving IVT injection of JP1 (40 µg) or RBZ (10 µg) once a week for 4 weeks showed significantly suppressed retinal vascular leakage. In both in vivo and in vitro experiments, JP1 counteracted oxidative stress and inflammation via inhibiting ROS/NF-κB signaling in microglial cells, and angiogenesis via modulating MEK1/2-SP1-integrin αVß3 and TRIM25-SP1-MMP2 axes in vascular endothelial cells. In addition, intraperitoneal injection of JP1 (1, 5 or 10 mg) once every other day for 3 times also dose-dependently inhibited CNV. After intraperitoneal injection of FITC-labeled JP1 (FITC-JP1) or FITC in laser-induced CNV mice, the fluorescence intensity in the CNV lesion was markedly increased in FITC-JP1 group, compared with that in FITC group, confirming that JP1 could penetrate the blood-retinal barrier to target CNV lesion. We conclude that JP1 can be used to design novel CNV-targeting therapeutic agents that may replace current invasive intraocular injections.


Asunto(s)
Neovascularización Coroidal , Diabetes Mellitus Experimental , Retinopatía Diabética , Animales , Ratones , Inhibidores de la Angiogénesis/farmacología , Inhibidores de la Angiogénesis/uso terapéutico , Neovascularización Coroidal/tratamiento farmacológico , Neovascularización Coroidal/metabolismo , Neovascularización Coroidal/patología , Diabetes Mellitus Experimental/tratamiento farmacológico , Retinopatía Diabética/tratamiento farmacológico , Modelos Animales de Enfermedad , Células Endoteliales/metabolismo , Fluoresceína-5-Isotiocianato/uso terapéutico , Integrina alfaVbeta3/uso terapéutico , Péptidos/uso terapéutico
2.
Mini Rev Med Chem ; 18(2): 164-172, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-28245783

RESUMEN

Shikonin, alkannin and their derivatives, the main ingredient of Lithospermum erythrorhizon and Arnebia euchroma (Royle) Johnst native to Inner Mongolian and Northwest of China respectively, hold promising potentials for antitumor effects via multiple-target mechanisms. This review will emphasize the importance of their antitumor activity in apoptosis, necroptosis and immunogenic cell death, and expound the relationship of their antitumor activity and naphthoquinone scaffold that could generate ROS and alkylating agent. Meanwhile, the antitumor mechanisms of naturally-occurring shikonin, alkannin and their derivatives, which were divided into the direct interaction involved in alkylating agent, covalently binding the DNA and protein, as well as the indirect interaction mediated by ROS, nonspecifically influencing the mitochondria or multiple signal pathways, will be systematically summarized and discussed.


Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Naftoquinonas/farmacología , Neoplasias/tratamiento farmacológico , Antineoplásicos Fitogénicos/química , Apoptosis/efectos de los fármacos , Muerte Celular/efectos de los fármacos , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Lithospermum/química , Naftoquinonas/química , Neoplasias/patología , Especies Reactivas de Oxígeno/metabolismo
3.
Medicine (Baltimore) ; 96(31): e7519, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28767570

RESUMEN

This study aims to explore the effect of oxycodone hydrochloride injection on the immune function of patients who underwent radical resection of rectal cancer under general anesthesia.Eighty patients were enrolled and randomly divided into group A and B (n = 40, each). All patients underwent general intravenous anesthesia. At the end of surgery, each patient in group A was injected with 5 mg (5 mL) of oxycodone hydrochloride, while 5 mg (5 mL) of morphine hydrochloride in group B. Venous blood was withdrawn in both groups at different time points. Changes in the numbers of T lymphocyte subsets and natural killer (NK) cells were determined by flow cytometry.First the numbers of T lymphocyte subsets and NK cells at T1, T2, T3, and T4 decreased in both groups, compared with those at T0, and the differences were statistically significant. Furthermore, the numbers reduced to a minimum at T2 and began to recover at T3. Second the differences between group A and B at T1, T2, T3, and T4 were statistically significant; and the numbers of T lymphocytes and NK cells were higher in group A than in group B at corresponding time points.Oxycodone hydrochloride and morphine hydrochloride both have inhibitory effects on immune function in patients undergoing radical resection of rectal cancer after surgery. However, oxycodone hydrochloride has a smaller effect compared to morphine hydrochloride.


Asunto(s)
Analgésicos Opioides/uso terapéutico , Anestesia General , Oxicodona/uso terapéutico , Neoplasias del Recto/tratamiento farmacológico , Neoplasias del Recto/cirugía , Analgésicos Opioides/efectos adversos , Biomarcadores/sangre , Femenino , Humanos , Factores Inmunológicos/efectos adversos , Factores Inmunológicos/uso terapéutico , Masculino , Persona de Mediana Edad , Morfina/uso terapéutico , Oxicodona/efectos adversos , Neoplasias del Recto/sangre , Neoplasias del Recto/inmunología , Resultado del Tratamiento
4.
Chem Biol Drug Des ; 87(6): 895-904, 2016 06.
Artículo en Inglés | MEDLINE | ID: mdl-26804061

RESUMEN

DMAKO-05((S)-1-((5E,8E)-5,8-bis(hydroxyimino)-1,4-dimethoxy-5,8-dihydronaphthalen-2-yl)-4-methylpent-3-enyl 3-methylbutanoate) is a novel oxime derivative of shikonin, the major component extracted from Chinese herb Lithospermun erythrorhizon. Here, we report that DMAKO-05 had an antitumor activity against mouse melanoma cell line B16F0. Our studies indicated that DMAKO-05 not only inhibited B16F0 proliferation and migration but also led to cell cycle arrest at G1 phase and cell apoptosis, in which DMAKO-05 triggered mitochondrial-mediated apoptosis signal including caspase-9/3 and PARP. In response to DMAKO-05 treatment, the Akt-mediated survival signals were remarkably attenuated in B16F0 cells. Collectively, DMAKO-05 has a strong cytotoxicity in B16F0 cells via inhibiting Akt activation, inducing G1 arrest, and promoting B16F0 cell apoptosis. DMAKO-05 might serve as a potential candidate lead compound for melanoma.


Asunto(s)
Antineoplásicos Fitogénicos , Proliferación Celular/efectos de los fármacos , Melanoma , Naftoquinonas , Proteínas Proto-Oncogénicas c-akt/metabolismo , Transducción de Señal/efectos de los fármacos , Animales , Antineoplásicos Fitogénicos/síntesis química , Antineoplásicos Fitogénicos/química , Antineoplásicos Fitogénicos/farmacología , Línea Celular Tumoral , Ensayos de Selección de Medicamentos Antitumorales , Melanoma/tratamiento farmacológico , Melanoma/metabolismo , Naftoquinonas/síntesis química , Naftoquinonas/química , Naftoquinonas/farmacología , Ratas
5.
ChemMedChem ; 9(12): 2798-808, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25234005

RESUMEN

To minimize the cytotoxicity of shikonin and alkannin that arises through the generation of reactive oxygen species (ROS) and alkylation of the naphthazarin ring, two series of novel core-scaffold-modified shikonin and alkannin derivatives were designed. These derivatives, which differ in their configurational and positional isomerism (R-, S-, and 2- and 6-isomers) were synthesized in high enantiomeric excess (>99 % ee). The selectivity of the dimethylated derivatives was significantly higher than the parent shikonin in vitro, but some side effects were still observed in vivo. Surprisingly, the dimethylated diacetyl derivatives with poor anticancer activity in vitro showed tumor-inhibiting effects similar to paclitaxel without any toxicity in vivo. The anticancer activity of these derivatives is in agreement with their low ROS generation and alkylating capacity, emphasizing their potential as prodrugs. This strategy provides means to address the nonspecific cytotoxicity of naphthazarin analogues toward normal cells.


Asunto(s)
Antineoplásicos/síntesis química , Diseño de Fármacos , Naftoquinonas/química , Profármacos/síntesis química , Alquilación , Animales , Antineoplásicos/uso terapéutico , Antineoplásicos/toxicidad , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Femenino , Masculino , Ratones , Microsomas Hepáticos/metabolismo , Naftoquinonas/uso terapéutico , Naftoquinonas/toxicidad , Neoplasias/tratamiento farmacológico , Neoplasias/patología , Profármacos/uso terapéutico , Profármacos/toxicidad , Ratas , Especies Reactivas de Oxígeno/metabolismo , Estereoisomerismo , Relación Estructura-Actividad , Trasplante Heterólogo , Trasplante Homólogo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA